IMUC

ImmunoCellular Therapeutics, Ltd. [IMUC] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IMUC Stock Summary

In the News

IMUC Financial details

Company Rating
-
Market Cap
16.1M
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
-0.09
Forward P/E
-
PEG
-
P/S
-
P/B
0.36
P/C
-
P/FCF
-2.72
Quick Ratio
2.81
Current Ratio
2.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-13.33%
SMA50
-7.14%
SMA100
44.44%
Inst Own
-
Inst Trans
-
ROA
-264%
ROE
-344%
ROC
-4.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.11-0.4
52W High
-
52W Low
-
RSI
53.71
Rel Volume
2.24
Avg Volume
3.35K
Volume
7.5K
Perf Week
6.25%
Perf Month
-4.97%
Perf Quarter
112.5%
Perf Half Y
91.44%
-
-
-
-
Beta
1.192
-
-
Volatility
0.04%, 0.04%
Prev Close
126.67%
Price
0.17
Change
38.1%

Something similar

Top by Market Cap
ABEA.DE
V
TL0.DE
1YD.DE
ABEC.DE
Same Sector
SRDX
AMYT.L
GTHX
INTP
DIA.MI
Same Price Range
AERI.L
ATXG
ENRT
2212.HK
0660.HK
Similar Market Cap
8147.HK
EDR.L
QSEP
DTRL
8121.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 3.35K
  • Market Capitalization 16.1M
  • Employee 3
  • CEO Dr. Irach B. Taraporewala B.S., M.S., Ph.D.
  • Headquarters Montvale,NJ,US
  • IPO Date 2021-01-08
  • Website https://www.eompharma.com

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.